Gipertonicheskie krizy: lechebno-diagnosticheskaya taktika na dogospital'nom etape


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This article describes current principles of diagnosis and treatment of uncomplicated and complicated hypertensive crises during prehospital stage. Special attention is paid to differential approach to the treatment of patients with hypertensive crisis, which takes into account individual characteristics of the disease, pattern of target organ damage and existence of comorbidity.

Full Text

Restricted Access

References

  1. Гапонова Н.И., Плавунов Н. Ф., Бараташвили В.Л., Абдрахманов В.Р. Клиникостатистический анализ артериальной гипертензии, осложненной гипертоническим кризом, в Москве за 2005-2009 гг. // Кардиология 2011. Т. 51. № 2. С. 40-4.
  2. Голиков А.П., Лукьянов М.М., Руднев Д.В. Тактика лечения и профилактика кризов у больных гипертонической болезнью на фоне ишемической болезни сердца. Методические рекомендации. М., 2005. 79 с.
  3. Колос И.П., Чазова И.Е., Терещенко С.Н. и др. Риск развития сердечно-сосудистых осложнений у пациентов с частыми гипертоническими кризами. Предварительные результаты многоцентрового ретроспективного исследования случай-контроль ОСАДА// Тер. архив 2009. № 9. С. 9-12.
  4. Терещенко С.Н. Гипертонические кризы: диагностика и лечение// В кн.: "Руководство по артериальной гипертонии"/ Под ред. Е.И. Чазова, И.Е. Чазовой. М., 2005. С. 677-89.
  5. Терещенко С.Н., Гапонова Н.И., Абдрахманов В.Р. и др. РАндомизированное многоцентровое сравнительное исследование эффективности моксонидина у больных с неосложненным гипертоническим кризом (AVES) // Артериальная гипертензия 2011. Т. 17. № 4. С. 316-24.
  6. Шамалов Н.А., Губский Л.В., Рамазанов Г.Р. и др. Динамика КТ-перфузионных показателей в острейшем периоде ишемического инсульта // Неврология и психиатрия 2012. Выпуск 2. № 3. С. 1-6.
  7. Adnot S, Defouilloy C, Brun-Buisson C, et al. Hemodynamic effects of urapidil in patients with pulmonary hypertension. Am Rev Respir Dis 1987;135:288-93.
  8. Adnot S, Andrivet P, Piquet J, et al. The effects of urapidil therapy on hemodynamics and gas exchange in exercising patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am Rev Respir Dis 1988;137;1068-74.
  9. Arima H, Anderson CS, Wang JG, et al. Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial Investigators. Lower treatment blood pressure is associated with greatest reduction in hematoma growth after acute intracerebral hemorrhage. Hypertension 2010;56(5):852-58.
  10. Chazova I, Almazov VА, Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabets, Obesity and Metabolism 2006;8:456-65.
  11. Eichstadt H, Gatz G, Schroder R, et al. Left ventricular hypertrophy regression with moxonidine therapy. J Pharmacol Ther 1991;1:12-7.
  12. Ernsberger PR, Westbrooks KL, Christen MO, et al. A second generation of cenrrally acting antihypertensive agents act on putative II-imidazoline receptors. Cardiovasc Pharmacol 1992;20 (Suppl. 4):1-10.
  13. European Society of Hypertension - European Society of Cardiology guidelines for manage ment of arterial hypertension. J Hypertension 2003;21:1011-53.
  14. Frei M, Kuster l, Gardosch von Krosigk P-P, et al. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. Cardiovasc Pharmacol 1994;24:25-8.
  15. Haczynski J, Spring A, Przewlocka-Kosmala M, et al. Effect of moxonidine on left ventricular hypertrophy in hypertensive patients. Clin Basic Cardiol 2001;4:61-5.
  16. Huggett RJ, Scott EM, Gilbey SG, et al. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003;108:3097-101.
  17. Huting J, Mitrovic V, Bahavar H. Comparison of the effects of moxonidine and nifedipine on left ventricular function during monotherapy of essential hypertension. Herz-Kreislauf 1992;24:132-36.
  18. JNC VII - The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. U.S. Department of Health and Human Servies. National Institutes of Health. National Heart, Ling and Blood Institute. National High Blood Pressure Education Program - NIH Publication 2003;03:5233.
  19. Julius S, Valentini M. Conseguences of the increased autonomic nervous drive in hypertension, heart failure and diabetes. Blood Press, 1998;7(3):5-13.
  20. Kablau M, et al. Predictors and early outcome of hemorrhagic transformation after acute ischemic stroke. Cerebrovasc Disease 2011;32(4):334-41.
  21. Kraft K, Vetter H. Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension; moxonidine versus captopril. Cardiovasc Pharmacol 1994;24(1):29-33.
  22. Kuppers H, E, Jager BA, Luszick JH, et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enelapril in mild-to-moderate essential hypertension. Hypertens 1997;15:93-7.
  23. Lotti G, Gianrossi R. Moxonidin vs. captopril in mild-to-moderate hypertension (German). Fortschr Med 1993;111(27);429-32.
  24. Messe SR. CT-NIHSS mismatch does not cor relate with MRI diffusion-perfusion mismatch. Stroke 2007;38(7):2079-84.
  25. Mitrovic V, Patyna W, Huting J, Schlepper M. Hemodynamic and neutohymoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991;5:967-72.
  26. Prichard BNC, Simmons R, Rooks MJ, et al. A double-blind comparison of moxonidine and atenolol in the management of patients with mild-to-moderate hypertension. Cardiovasc Pharmacol 1992;20:45-9.
  27. Prichard BNC. Clinical pharmacology of moxonidine. In; van Zwieten PA, et al, editors. The I1-Imidazoline Receptor Agonist Moxonidine. 2nd Edition. London: Roy Soc Med 1996:31-47.
  28. Prichard BNC, Kuster LJ, Hughes PR, et al. Dose relation of blood pressure reduction with moxonidine: findings from three placebo- and active-controlled randomized studies. Clin Basic Cardiol 2003;6:49-51.
  29. Radermacher J, Mengel M, Ellis S, et al. The renal arterial resistance index and renal allograft survival. New Engl J Med 2003;349:115-24.
  30. Sanjuliani AE, Genelhu de Abreu V, Ueleres Braga J, Francischetti EA. Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin and metabolic profile in obese hypertensive patients. Clin Basic Cardial 2004;7;19-25.
  31. Van Onzenoort HA, Bussink M, Menheere PP, et al. The effect of sublingual captopril versus intravenous enalaprilat on angiotensin II plasma levels. Pharm World Sci 2006;28:131-34.
  32. Wolf R. The treatment of hypertensive patients with a calcium antagonist or moxonidine:a comparison. J Cardiovasc Pharmacol 1992; 20:42-4.
  33. Word Heals Organization - International society of Hypertention Guidelines for the Management of Hypertention. Hypertens 1999;17:151-83.
  34. Webster J, Petrie JC, Jeffers TA, et al. Accelerated hypertension - patterns of mortality and clinical factors affecting outcome in treated patients. Q J Med 1993;86(8):485-93.
  35. Zampaglione B. Hypertensive urgencies and emergencies. Prevalence and clinical presentation /Zampaglione B, Pascale C, Marchisio M, et al. Hypertension 1996;27:144-47.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies